Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation

American Journal of Health-System Pharmacy

Volumn 62, Issue SUPPL. 4, 2005, Pages

  Levy, Jerrold H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aprotinin; Blood; Coronary artery bypass; Desmopressin; Factor VIIa; Hemostatics; Mechanism of action; Mortality; Pituitary hormones; Toxicity

Indexed keywords

APROTININ; BLOOD CLOTTING FACTOR 7A; DESMOPRESSIN; HYPOPHYSIS HORMONE; LYSINE DERIVATIVE;

BLEEDING; BLOOD STORAGE; BLOOD TRANSFUSION; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

EID: 24944553374     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050303     Document Type: Conference Paper

References (31)

1. Spiess BD, Royston D, Levy JH et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004; 44(8):1143-8.
2. Trasylol® (aprotinin injection) package insert. West Haven, CT: Bayer Pharmaceuticals Corporation; 2003 Dec.
3. Cyklokapron® (tranexamic acid tablets and tranexamic acid injection) package insert. Kalamazoo, MI: Pharmacia Corporation; 2001 Dec.
4. DDVAP® desmopressin acetate injection package insert. Limhamn, Sweden: Ferring Pharmaceuticals Inc.; 2003 Apr.
5. Novoseven® Coagulation Factor VIIa (Recombinant) package insert. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc.; 2004 Aug.
6. Amicar® (aminocaproic acid), injection, syrup, and tablets, package insert. Florence, KY: Xanodyne Pharmaceuticals, Inc.; 2004 Sept.
7. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology. 1994; 80(5):1013-8.
8. Lemmer JH, Jr., Stanford W, Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 1994; 107(2):543-51.
9. Levy JH, Pifarre R, Schaff HV et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation. 1995; 92(8):2236-44.
10. Alderman EL, Levy JH, Rich JB et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998; 116(5):716-30.
11. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004; 128(3):442-8.
12. Smith PK, Muhlbaier LH. Aprotinin: safe and effective only with the full-dose regimen. Ann Thorac Surg. 1996; 62(6):1575-7.
13. Asimakopoulos G, Thompson R, Nourshargh S et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000; 120(2):361-9.
14. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001; 71(2):745-54.
15. Day JR, Punjabi PP, Randi AM et al. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation. 2004; 110(17):2597-600.
16. Poullis M, Manning R, Laffan M et al. The antithrombotic effect of aprotinin: actions mediated via the protease-activated receptor 1. J Thorac Cardiovasc Surg. 2000; 120(2):370-8.
17. Casati V, Guzzon D, Oppizzi M et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions. J Thorac Cardiovasc Surg. 2000; 120(3): 520-7.
18. Salzman EW, Weinstein MJ, Weintraub RM et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med. 1986; 314(22): 1402-6.
19. Hackmann T, Gascoyne RD, Naiman SC et al. A trial of desmopressin (1-desamino-8-D-arginine vasopressin) to reduce blood loss in uncomplicated cardiac surgery. N Engl J Med. 1989; 321(21):1437-43.
20. Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery, a meta-analysis of clinically relevant end-points. Lancet. 1999; 354(9194):1940-7.
21. Friederich PW, Levi M, Bauer KA et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 2001; 103(21):2555-9.
22. Hoffman M, Monroe DM, Roberts HR. Platelet-dependent action of high-dose factor VIIa. Blood. 2002; 100(1):364-5.
23. Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002; 106(20):2550-4.
24. Hedner U, Erhardtsen E. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI. Ann Med. 2000; 32 Suppl: 168-72.
25. Gabriel DA, Li X, Monroe DM, 3rd et al. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost. 2004; 2(10):1816-22.
26. Tanaka KA, Waly AA, Cooper WA et al. Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology. 2003; 98 (6):1513-5.
27. von Heymann C, Hotz H, Konertz W et al. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002; 16(5):615-6.
28. Kastrup M, von Heymann C, Hotz H et al. Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg. 2002; 74(3):910-2.
29. Tobias JD, Berkenbosch JW, Muruve NA et al. Correction of a coagulopathy using recombinant factor VII before removal of an intra-aortic balloon pump. J Cardiothorac Vasc Anesth. 2002; 16(5):612-4.
30. Hendriks HG, van der Maaten JM, de Wolf J et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg. 2001; 93(2):287-9.
31. Stratmann G, Russell IA, Merrick SH. Use of recombinant factor VIIa as a rescue treatment for intractable bleeding following repeat aortic arch repair. Ann Thorac Surg. 2003; 76(6):2094-7.